Xgene’s non-opioid analgesic reduces pain in Phase IIb trial
A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in post-surgery pain compared to placebo.
03 January 2025
03 January 2025
A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in post-surgery pain compared to placebo.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.